Gerresheimer Manufactures Insulin Pen for Big Pharma Company


Gerresheimer AG has recently commenced the commercial production of the ClikSTAR® insulin pens for sanofi-aventis. Medical plastic systems, such as insulin pens, will be increasingly important in the Gerresheimer product portfolio in the future because they incorporate a dosage and application function in addition to being a pure medication packaging.

The industrialization of the insulin pen was prepared in Wackersdorf, the Gerresheimer Plastics Division’s technology center. Gerresheimer’s Pfreimd plant (Germany) is the place where the individual components are manufactured and assembled under clean room conditions.

“We are delighted about this sanofi-aventis production project because it involves a complex product that demonstrates our leadership in the medical plastic systems market to the pharma industry,” said Uwe Röhrhoff, Chief Executive Officer of Gerresheimer AG.

The re-usable ClikSTAR insulin pen has received the Good Design Award. Insulin pens are drug delivery systems in pen format that enable diabetes sufferers to reliably administer their regular insulin doses in a virtually pain-free procedure. Diabetes treatment is gaining in significance from year to year. According to World Health Organization (WHO) estimates, there will be around 350 million diabetes sufferers in the world by the year 2030. ClikSTAR is a registered trademark of sanofi-aventis.

Gerresheimer is an internationally leading manufacturer of high-quality specialty products made of glass and plastic for the global pharma and healthcare industry. Its comprehensive portfolio of products extends from pharmaceutical vials to complex drug delivery systems, such as syringe systems, insulin pens, and inhalers for safe medication dosage and application.